Food Engineering / Gıda Mühendisliği

Permanent URI for this collectionhttps://hdl.handle.net/11147/12

Browse

Filters

20162

Settings

Author: search.filters.author.Sezgin, EfeScopus Q: search.filters.scopusQuartile.Q4

Search Results

Now showing 1 - 2 of 2
  • Article
    Evrimsel epidemiyoloji: Epidemiyoloji ve evrimsel biyolojinin sentezi
    (Türk Tabipleri Birliği, 2016) Sezgin, Efe
    Epidemiology investigates the distribution and causes of health and disease among individuals and populations. Evolutionary medicine, in other words Darwinian medicine, is a new discipline that aims to bring novel approaches to health problems that traditional medicine cannot understand and cannot find cures for, in order to improve the overall health of human populations. Epidemiology, the primary discipline of public health, is one of the medical branches that benefited the most from evolutionary approaches in medicine. Traditional epidemiology focuses on proximate causes and seeks answers to 'what' and 'how' questions on the dynamics between factors, environment, and humans. Evolutionary epidemiology focuses on the ultimate causes of diseases and seeks answers to 'how' and 'why' questions on the origin and function. In order to find answers, it compares the evolutinary process of Homo sapiens (modern humans) with that of its relatives, it examines the fast changes in human ecology, demographic and social dynamics, it looks at the epidemiology of modern diseases from an evolutionary process perspective. Using contemporary molecular and statistical genetic methods, it examines the contemporary human genetic variation and its evolution. It searches why diseases causing genetic variation are still not eliminated from human populations. Adaption of evolutionary ideas into epidemiologic research will enhance population health and provide novel solutions for diseases.
  • Article
    Citation - Scopus: 37
    The Impact of Onco Type Dx® Recurrence Score of Paraffin-Embedded Core Biopsy Tissues in Predicting Response To Neoadjuvant Chemotherapy in Women With Breast Cancer
    (IOS Press, 2016) Soran, Atilla; Bhargava, Rohit; Johnson, Ronald; Ahrendt, Gretchen; Bonaventura, Marguerite; Diego, Emilia; McAuliffe, Priscilla F.; Serrano, Merida; Menekşe, Ebru; Sezgin, Efe; McGuire, Kandace P.
    BACKGROUND: Oncotype DX® test is beneficial in predicting recurrence free survival in estrogen receptor positive (ER+) breast cancer. Ability of the assay to predict response to neoadjuvant chemotherapy (NCT) is less well-studied. OBJECTIVE: We hypothesize a positive association between the Oncotype DX® recurrence score (RS) and the percentage tumor response (%TR) after NCT. METHODS: Pre-therapy RS was measured on core biopsies from 60 patients with ER+, HER2.. invasive breast cancer (IBC) who then received NCT. Pre-therapy tumor size was measured using imaging. %TR, partial response (PR; 50%), pathologic complete response (PCR) and breast conserving surgery (BCS) rates were measured. RESULTS: Median RS was 20 (2 69). Median %TR was 42 (0 97)%. PR was observed in 43% of patients. There was no association between %TR and pre-NCT tumor size, age, Nottingham score or nodal status (p 0:05). No statistically significant association with %TR was seen with RS as a categorical or continuous variable (p = 0:21 and 0.7, respectively). Response to NCT improved as ER (p = 0:02) by RT-PCR decreased. Lower ER expression by IHC correlated with response (p = 0:03). CONCLUSIONS: In patients with ER+ IBC receiving NCT, RS did not predict response to NCT using %TR. The benefit of the assay prior to NCT requires further study.